Jaye Thompson Buys 800 Shares of Greenwich LifeSciences, Inc. (NASDAQ:GLSI) Stock

Greenwich LifeSciences, Inc. (NASDAQ:GLSI) VP Jaye Thompson acquired 800 shares of the company’s stock in a transaction dated Monday, August 12th. The stock was acquired at an average cost of $13.85 per share, for a total transaction of $11,080.00. Following the completion of the purchase, the vice president now directly owns 263,148 shares in the company, valued at $3,644,599.80. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link.

Jaye Thompson also recently made the following trade(s):

• On Friday, August 2nd, Jaye Thompson bought 1,000 shares of Greenwich LifeSciences stock. The shares were acquired at an average cost of $15.15 per share, with a total value of $15,150.00.
• On Thursday, July 18th, Jaye Thompson purchased 1,000 shares of Greenwich LifeSciences stock. The shares were acquired at an average price of $16.00 per share, for a total transaction of $16,000.00.

Greenwich LifeSciences Stock Down 2.0 %

NASDAQ GLSI opened at $14.17 on Thursday. Greenwich LifeSciences, Inc. has a 52 week low of $7.58 and a 52 week high of $21.44. The business has a 50 day moving average price of $14.58 and a 200-day moving average price of $15.12. The company has a market cap of $182.51 million, a price-to-earnings ratio of -19.68 and a beta of 1.61.

Greenwich LifeSciences (NASDAQ:GLSI) last posted its quarterly earnings data on Wednesday, August 14th. The company reported ($0.20) earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of ($0.20). On average, equities research analysts anticipate that Greenwich LifeSciences, Inc. will post -0.81 earnings per share for the current year.

Hedge Funds Weigh In On Greenwich LifeSciences

A number of hedge funds and other institutional investors have recently made changes to their positions in GLSI. Vanguard Group Inc. increased its holdings in Greenwich LifeSciences by 0.6% during the first quarter. Vanguard Group Inc. now owns 223,102 shares of the company’s stock worth $4,449,000 after buying an additional 1,420 shares during the last quarter. Rhumbline Advisers purchased a new position in Greenwich LifeSciences in the second quarter valued at about $117,000. Finally, Bank of New York Mellon Corp bought a new position in shares of Greenwich LifeSciences during the 2nd quarter valued at approximately $264,000. 4.16% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

Separately, HC Wainwright boosted their target price on shares of Greenwich LifeSciences from $36.00 to $38.00 and gave the company a “buy” rating in a research report on Friday, August 23rd.

About Greenwich LifeSciences

Greenwich LifeSciences, Inc, a clinical-stage biopharmaceutical company, develops novel cancer immunotherapies for breast cancer and other HER2/neu-expressing cancers. Its lead product candidate is GP2, an immunotherapy, which is in Phase III clinical trial to prevent breast cancer recurrences in patients who have previously undergone surgery.